1556 related articles for article (PubMed ID: 24141036)
1. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
2. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
4. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
5. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
7. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
11. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
13. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
15. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
17. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
19. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Bonnick S; Saag KG; Kiel DP; McClung M; Hochberg M; Burnett SM; Sebba A; Kagan R; Chen E; Thompson DE; de Papp AE
J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
